Merck Stock Upgraded Amid Acquisition Talks
Wolfe Research upgraded Merck to Outperform with a $135 target on January 8. On January 9, reports emerged of Merck in talks to acquire Revolution Medicines for around $30 billion.
Topic
Latest reporting and analysis tagged with Merck.
Wolfe Research upgraded Merck to Outperform with a $135 target on January 8. On January 9, reports emerged of Merck in talks to acquire Revolution Medicines for around $30 billion.